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Mechanism of Selective VEGF-A Binding by Neuropilin-1
Reveals a Basis for Specific Ligand Inhibition
Matthew W. Parker, Ping Xu, Hou-Fu Guo, Craig W. Vander Kooi*
Department of Molecular and Cellular Biochemistry and Center for Structural Biology, University of Kentucky, Lexington, Kentucky, United States of America
Abstract
Neuropilin (Nrp) receptors function as essential cell surface receptors for the Vascular Endothelial Growth Factor (VEGF)
family of proangiogenic cytokines and the semaphorin 3 (Sema3) family of axon guidance molecules. There are two Nrp
homologues, Nrp1 and Nrp2, which bind to both overlapping and distinct members of the VEGF and Sema3 family of
molecules. Nrp1 specifically binds the VEGF-A164/5 isoform, which is essential for developmental angiogenesis. We
demonstrate that VEGF-A specific binding is governed by Nrp1 residues in the b1 coagulation factor domain surrounding
the invariant Nrp C-terminal arginine binding pocket. Further, we show that Sema3F does not display the Nrp-specific
binding to the b1 domain seen with VEGF-A. Engineered soluble Nrp receptor fragments that selectively sequester ligands
from the active signaling complex are an attractive modality for selectively blocking the angiogenic and chemorepulsive
functions of Nrp ligands. Utilizing the information on Nrp ligand binding specificity, we demonstrate Nrp constructs that
specifically sequester Sema3 in the presence of VEGF-A. This establishes that unique mechanisms are used by Nrp receptors
to mediate specific ligand binding and that these differences can be exploited to engineer soluble Nrp receptors with
specificity for Sema3.
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Introduction
The Nrp family of receptors coordinate ligand-binding events
that mediate endothelial cell migration and proliferation and
neuronal chemorepulsion (reviewed in [1]). There are two Nrp
homologues, Nrp1 and Nrp2, which share the same overall
domain architecture with 44% identity in their primary sequence.
Nrp ligands include the VEGF family of pro-angiogenic cytokines
[2] and the Sema3 family [3,4] of axon guidance molecules [5].
Both VEGF and Sema3 family of ligands are composed of
multiple genes, splice forms, and proteolytic products with
different receptor binding specificity and physiological function.
Soluble receptors capable of sequestering specific ligands are an
attractive modality for blocking ligand-dependent signaling path-
ways. VEGF-Trap, a soluble chimera of VEGF receptor
(VEGFR), containing the domains necessary for ligand binding
[6], has been approved for use as a clinical agent blocking VEGF-
A dependent angiogenesis [7]. The identification of endogenously
expressed soluble Nrp receptors (sNrp) with anti-tumor activity [8]
has prompted interest in the use of engineered Nrp molecules as
specific pathway inhibitors. It was recently reported that mutation
to the Nrp2-b1 domain enhances its ability to bind VEGF-A [9]
and that administration of this truncated receptor effectively
antagonizes VEGF-A dependent angiogenic signaling [10]. A
Sema3 specific inhibitor would be of significant utility. While
Sema3 mediated repulsive cues are essential during development,
they pose a significant barrier to axonal regrowth following injury
[11]. This is particularly the case in repair following spinal cord
injury. In response to spinal cord injury a glial scar forms that
serves as a barrier to regenerating axons. Sema3 family members
are produced by meningeal cells located in the glial scar and are
a major component of the repulsive cues that prevent axonal
regeneration [12,13]. Blocking inhibitory cues represents one
fundamental mode of regenerative therapy for partial cord injuries
[14]. However, due to limited understanding of the determinants
of Nrp binding specificity, no soluble Nrp-trap exists that is specific
for Sema3.
The conserved Nrp architecture provides Nrp homologues with
the ability to bind ligands using a common binding mode. The b1
coagulation factor domain of Nrp1 and Nrp2 contains a conserved
cleft optimally suited for binding a C-terminal arginine that is
necessary for ligand binding [15–17]. All VEGF family members
contain a C-terminal arginine and all Sema3 family members
contain at least one conserved furin recognition sequence that is
endogenously cleaved to liberate a C-terminal arginine [18,19].
Indeed, binding to this shared site underlies the observed
competition between VEGF and Sema3 [9,19].
In physiological context, physical and functional specificity is
observed between receptor-ligand pairs. Nrp1 acts as the
functional receptor for VEGF-A [2] and Sema3A [3,4] and
Nrp2 acts as the functional receptor for VEGF-C [20] and
Sema3F [21]. The mechanism underlying specific Sema3 family
member binding by Nrp1 and Nrp2 has been shown to involve
dual-site binding. The Nrp b1 domain binding to the Sema3 C-
terminal domain is necessary for high-affinity binding but does not
display specificity for Nrp1 or Nrp2 [19,21]. Secondarily, the N-
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terminal a1 domain of Nrp1 and Nrp2 selectively binds the sema
domain of different Sema3 family members [22–24]. Indeed,
a Sema3 binding-deficient Nrp has been reported which disrupts
the unique a1/sema interaction [25]. However, since there is no
known secondary binding site, the basis for specificity in VEGF
binding remains unclear.
It was recently demonstrated that the essential VEGF-A164/165
(VEGF-A) isoform binds preferentially to Nrp1 [16]. The C-
terminal arginine binding cleft of the Nrp1-b1 domain is formed
by three loops which are a common feature among coagulation
factor domains. While the cleft is conserved, a significant number
of residues surrounding this binding pocket differ between Nrp1
and Nrp2 and may contribute to the observed ligand binding
specificity. Indeed, the L1 loop of the Nrp b1 domain has been
shown to contribute to the observed preferential binding of
VEGF-A to Nrp1 [16]. However, this interaction alone is
insufficient to explain the marked difference in potency of
VEGF-A binding to Nrp1 and Nrp2, therefore other molecular
determinants of this preferential binding must exist. The recently
reported Nrp2 mutation, when Nrp2 R287 is replaced with the
corresponding Nrp1 E285, shows enhanced VEGF-A binding and,
importantly, unchanged binding to Sema3F [9]. Together, these
data suggest that the Nrp b1 domain contains distinct features that
govern specific ligand binding and could be exploited to produce
specific inhibitors of Nrp ligands. By understanding how selective
VEGF binding is achieved, and whether these regions also affect
Sema3 binding, a Nrp molecule that specifically bound Sema3 and
blocked Sema3 repulsive cues could be designed as a potentially
important therapeutic tool.
In the present study we determined the basis for preferential
Nrp1 binding to VEGF-A. Mutagenesis of residues surrounding
the shared C-terminal arginine binding pocket identifies residues
that differ between Nrp1 and Nrp2 and underlie the observed
VEGF-A specificity. A chimeric Nrp2, which combines the
identified mutations, is capable of binding VEGF-A similarly to
Nrp1 whereas a chimeric Nrp1 shows significant loss of VEGF-A
binding. We further show that Nrp1 and Nrp2 both bind Sema3F
with similar affinity and that both Nrp2 and the chimeric Nrp1
can selectively sequester Sema3. These data establish that unique
mechanisms are used by Sema3 and VEGF-A to mediate specific
Nrp binding, revealing a basis for the use of engineered Nrp
molecules as selective inhibitors of Sema3.
Materials and Methods
Protein Expression and Purification
The high affinity ligand binding b1b2 domains of human Nrp1
and Nrp2, and VEGF-A165 were expressed in Escherichia coli, as
previously reported, and purified according to established
procedures [15,19,26]. Chimeric Nrp1 and Nrp2 constructs were
generated using the megaprimer method, expressed as a 6XHis-
tag fusion from pET28, and purified using immobilized metal
affinity chromatography (IMAC) followed by heparin agarose
affinity, as with wild-type proteins. Proteins were buffer exchanged
into binding buffer (20 mM Tris pH 7.5, 50 mM NaCl).
Large-scale transient transfection of Chinese Hamster Ovary
(CHO) cells was used to express alkaline phosphatase (AP) fusion
proteins from pAPtag-5 (GenHunter, Nashville, TN) [19,27]. AP-
Nrp1 and AP-Nrp2 b1b2 mutants were generated using the
megaprimer method. All AP-Nrp wild-type and mutant proteins
were produced at similar levels. AP-Nrp conditioned media was
concentrated and buffer exchanged into binding buffer. All
expression plasmids and mutants were verified by DNA sequenc-
ing.
AP-VEGF-A Inhibition Assay
Nrp affinity plates were prepared by adding 100mL of Nrp1
diluted 1/10 in 50 mM Na2CO3 pH 10.4 to a final concentration
of 2.5 ng/ml in 96 well high-binding plates (Costar, 9018),
incubated for 1 hr at 37uC, washed with PBS-T (PBS, 0.1%
Tween20), and stored at 4uC. An AP-fusion of VEGF-A164 (AP-
VEGF-A) was utilized for VEGF inhibition experiments [19].
Nrp1 and Nrp2 were combined with AP-VEGF-A (155 mmole p-
NPP hydrolyzed/min/L) in incubation buffer (20 mM Tris
pH 7.5, 300 mM NaCl) to a final volume of 100mL and incubated
with the Nrp1 affinity plates for 1 hr at 25uC. Wells were washed
three times with PBS-T using an EL404 plate washer (BioTek,
Winooski, VT), and incubated with PBS-T for an additional
5 min. Wash solution was removed, and 100mL of 16AP Assay
Reagent [28] was added. The reaction was quenched by addition
of 100mL of 0.5 N NaOH. Evolved p-nitrophenol (p-NP) was
quantitated at 405 nm using a SpectraMax M5 plate reader
(Molecular Devices, Sunnyvale, CA). The IC50 was fit with
a nonlinear dose-response inhibition curve using Prism (Graphpad
Software, La Jolla, CA). The inhibitory potency of Nrp1Chimera
and Nrp2Chimera was determined using the same method.
AP-Nrp Binding Assay
To assess the role of the Nrp coagulation factor loops in VEGF-
A binding, we measured AP-Nrp binding to VEGF-A affinity
plates. Affinity plates were prepared by adding 100mL of VEGF-
A165 diluted 1/10 in 50 mM Na2CO3 pH 10.4 to a final
concentration of 50 ng/ml in 96 well plates. AP-Nrp constructs
(724 mmole p-NPP hydrolyzed/min/L) were incubated with
VEGF-A affinity plates for 1 hr at 25uC. Plates were washed
and retained AP activity quantitated as described above.
AP-Sema3F and AP-Sema3F-Ig-basic Inhibition Assay
Two AP-fusions of Sema3F were prepared, one corresponding
to full length Sema3F (AP-Sema3F; residues 20–779) and the other
an AP-fusion of the Sema3F Ig and basic domains (AP-Sema3F-
Ig-basic; residues 605–779), the domains necessary and sufficient
for binding the b1 coagulation factor domain of Nrp [22]. These
were used for semaphorin inhibition experiments by Nrp. Nrp1
and Nrp2 were combined with AP-Sema3F (648 mmole p-NPP
hydrolyzed/min/L) in incubation buffer and incubated in low
density Nrp1 affinity plates for 1 h at 25uC. Similarly, Nrp1 and
Nrp2 were combined with AP-Sema3F-Ig-basic (181 mmole p-
NPP hydrolyzed/min/L) in binding buffer and incubated in high
density Nrp1 affinity plates for 1 hr at 25uC. High density Nrp1
affinity plates were prepared by adding 100mL of Nrp1 diluted 1/
10 in 50 mM Na2CO3 pH 10.4 to a final concentration of 50 ng/
ml in 96 well plates. Plates were washed and retained AP activity
quantitated as described above.
C-furSema Inhibition Assay
Two peptides corresponding to the C-terminal basic domains of
furin processed Sema3A (C-furSema3A; residues 718–769) (Neo-
Peptide, Cambridge, MA) and Sema3F (C-furSema3F; residues
740–779 [19]) (LifeTein, South Plainfield, NJ) were synthesized,
oxidized to form the natural inter-molecular disulfide, and
purified. Peptides were resuspended and titrated with AP-
VEGF-A (100 mmole p-NPP hydrolyzed/min/L) in incubation
buffer and added to low density Nrp1 affinity plates for 1 h at
25uC. Plates were washed and retained AP activity quantitated as
described above.
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AP-VEGF-A Recovery Assay
To measure the preferential binding of Nrp1 and Nrp2 to
Sema3F or VEGF-A the potential of Nrp to promote the recovery
of C-furSema [19] mediated inhibition of AP-VEGF-A binding to
Nrp1 was assessed. Nrp1 and Nrp2 were combined with both AP-
VEGF-A (155 mmole p-NPP hydrolyzed/min/L) and C-furSe-
ma3F (45 nM, the concentration at which <90% inhibition is
achieved) in incubation buffer and added to low density Nrp1
affinity plates for 1 hr at 25uC. Plates were washed and retained
AP activity quantitated as described above. Retained AP-VEGF-A
was reported versus Nrp concentration as the percent of binding
observed relative to uninhibited AP-VEGF-A (no C-furSema).
Circular Dichroism
Circular dichroism (CD) spectra were collected using a Jasco J-
810 Spectropolarimeter. Wild-type and chimeric proteins were
added to a 0.1-cm-pathlength cuvette at 10mM in PBS pH 7.4.
Spectra were recorded at a speed of 20 nm/min using the average
of three accumulations over a range of 205–245 nm. Data are
reported as per residue molar ellipticity.
Results
Soluble Nrp1 Selectively Inhibits VEGF-A
To assay the inhibitory potency of Nrp1 and Nrp2, we tested
the ability of Nrp1 and Nrp2 to inhibit VEGF-A binding to Nrp1
affinity plates in a dose dependent manner (Figure 1). Nrp1 was
able to potently inhibit the binding of VEGF-A to Nrp1 affinity
plates with an IC50 = 1.8 mM (log IC50 =25.760.2) (black line,
Figure 1). In contrast, Nrp2 was able to inhibit binding only at the
highest concentrations with an IC50<310 mM (log
IC50 =23.560.4) (grey line, Figure 1). Each experiment was
performed in triplicate with unique protein preparations to
provide a direct measurement of inter-assay variability, with
11% inter-assay variability observed for Nrp1 compared to 3.5%
intra-assay variability (Figure S1). These data demonstrate, both
qualitatively and quantitatively, the robust quality and reproduc-
ibility of the reported data. The greater than 100-fold difference in
IC50 between Nrp1 and Nrp2 is consistent with the previously
reported VEGF binding selectivity [16].
Identification of the Regions of Nrp1 that Confer
Selective VEGF-A Binding
The selective ability of Nrp1 to inhibit VEGF-A binding led us
to consider the mechanism of this specificity. The predominant
Nrp structural determinants mediating VEGF-A binding have
been localized to domain b1 [9,16,25]. The b1 domains of Nrp1
and Nrp2 are 52% identical. Conserved between both are the
residues which form the C-terminal arginine binding pocket
demonstrated to be essential for VEGF-A/Nrp binding [15]
(Figure 2A, asterisk). Alignment of Nrp1 and Nrp2 b1 domains
reveals diversity in the primary sequence of residues surrounding
the binding pocket. There are three different categories of
residues: those that are well conserved in both Nrp1 and Nrp2,
those that are not well conserved, and those which are distinct
between Nrp1 and Nrp2 but well conserved within each ortholog.
We hypothesized that residues in this last category likely underlie
the observed specific Nrp1/VEGF-A binding. Further, residues
nearby the binding pocket, especially those in the coagulation-
factor loops (L1–L3) often utilized in ligand binding in co-
agulation-factor domain proteins [29], most likely underlie specific
binding.
Based on these two criteria, i.e., that residues are separately
conserved within Nrp1 and Nrp2 and that they are nearby the
binding site, four regions were selected: Nrp1:E285/Nrp2:R287,
Nrp1:299-TN-300/Nrp2:301-DGR-303, Nrp1:304-ER-305/
Nrp2:307-QQ-308, and Nrp1:350-KKK-352/Nrp2:353-QNG-
355 (Figure 2B). Mutant proteins were produced by swapping
the selected sequences between the two Nrp homologues. Nrp
residues that contribute to the observed specificity would be
expected to reduce Nrp1 binding and enhance Nrp2 binding when
reversed. These chimeric Nrp molecules were expressed with an
N-terminal AP tag. The binding of AP-Nrp constructs to VEGF-A
affinity plates was measured and normalized relative to wild-type
Nrp1 or Nrp2 binding. Reduced binding to VEGF-A was
observed for all Nrp1 chimeras relative to wild-type Nrp1
(Figure 2C), suggesting a role of these sequences in VEGF-A
binding. Three of the four Nrp2 chimeras showed enhanced
affinity for VEGF-A relative to wild-type Nrp2 (Figure 2D). The
reduction in VEGF-A binding for both Nrp1 ER/QQ and Nrp2
QQ/ER suggests that these mutations may destabilize the protein
and this mutation was therefore excluded from further study.
These results suggest that E285, 299-TN-300, and 350-KKK-352
of the Nrp1-b1 domain contribute to selective VEGF-A binding.
Nrp2Chimera Inhibits VEGF-A Binding
To assess whether the identified loops compose the pre-
dominant features of the Nrp1-b1 domain that confer specific
VEGF-A binding, we generated a Nrp1 and Nrp2 molecule which
incorporated all three different mutations in a single construct,
termed Nrp1Chimera and Nrp2Chimera. To ensure that the mutant
proteins were well folded, CD was utilized to assess wild-type and
chimeric constructs (Figure 3A). All proteins produce spectra
consistent with the expected b-sandwich architecture of the
protein. Further, wild-type and mutant proteins show superimpos-
able spectra demonstrating that the mutations are not structurally
deleterious. As a quantitative measure of the selectivity of
Figure 1. Nrp1 selectively inhibits VEGF-A binding. The ability of
Nrp1 and Nrp2 to selectively sequester AP-VEGF-A from Nrp1 adsorbed
on affinity plates was assessed. The amount of retained AP-VEGF-A was
measured and the Nrp concentration recorded where half-inhibition
was achieved. Nrp1 inhibited the binding of VEGF-A with an
IC50 = 1.8 mM (black line). Inhibition by Nrp2 was seen only at the
highest concentration of protein attainable with an estimated
IC50<310 mM (grey line). Experiments were performed in triplicate
and reported as the mean 61 S.D.
doi:10.1371/journal.pone.0049177.g001
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NrpChimera proteins for VEGF-A, we assayed the potency of
Nrp1Chimera and Nrp2Chimera in inhibiting AP-VEGF-A binding to
Nrp1 affinity plates (Figure 3B). The dose-dependent ability of
these constructs to inhibit VEGF-A binding was compared to wild-
type Nrp1 and Nrp2 (Figure 1). The Nrp1Chimera showed
a significant loss in potency, with an IC50 = 62 mM (log
IC50 =24.260.1) (blue line, Figure 3B), an over 30-fold loss in
potency compared to Nrp1 (black line, Figure 1). Strikingly,
Nrp2Chimera gained over 70-fold potency relative to Nrp2, with an
IC50 = 3.9 mM (log IC50 =25.460.2) (green line, Figure 3B),
nearly to the level observed for wild-type Nrp1.
Nrp1 and Nrp2 Equivalently Inhibit Sema3F Binding
VEGF and semaphorin are the two major ligand families of Nrp
receptors. The Sema3 family of ligands has been demonstrated to
bind Nrp receptors via a dual-site binding mechanism. The Sema3
semaphorin domain mediates specific ligand binding via the Nrp
a1 domain [23] and the Sema3 basic C-terminus mediates
common high-affinity binding to the Nrp b1b2 domains [25]. To
confirm that the Nrp1 and Nrp2 b1b2 domains bind to Sema3,
and that they do not display specificity, we measured their ability
to inhibit the binding of AP-Sema3F to Nrp1. Both Nrp1 and
Nrp2 showed a dose-dependent inhibition of AP-Sema3F binding
with equivalent observed potency for Nrp1, IC50 = 2.0 mM (log
IC50 =25.760.1), and Nrp2, IC50 = 2.7 mM (log
IC50 =25.660.3) (Figure 4A). To confirm that this interaction is
mediated by the C-terminal domains of Sema3, we assayed the
ability of Nrp1 and Nrp2 b1b2 domains to inhibit the binding of
AP-Sema3F-Ig-basic to Nrp1. Consistent with the potency against
full-length Sema3F, Nrp1 inhibited AP-Sema3F-Ig-basic binding
with an IC50 = 1.2 mM (log IC50 =25.960.1) and Nrp2 inhibited
AP-Sema3F-Ig-basic binding with an IC50 = 6.2 mM (log
IC50 =25.260.2) (Figure 4B).
These data demonstrate that the b1b2 domain of Nrp1 and
Nrp2 contain structural determinants capable of C-terminal
Sema3F binding and that this binding does not show specific
binding to the two Nrp homologues. To confirm that the
interaction between the basic domain of Sema3F and Nrp1-
b1b2 is conserved across the Sema3 family, and that this
interaction site overlaps with that for VEGF-A, we measured the
ability of a peptide corresponding to the C-terminus of both
Sema3F and Sema3A to inhibit VEGF-A binding. C-furSema3F
and C-furSema3A, peptides corresponding to the furin-activated
forms of Sema3F and Sema3A, respectively, were assayed for their
ability to competitively inhibit the binding of VEGF-A. Both
peptides showed potent, dose-dependent inhibition of AP-VEGF-
A binding with IC50 = 22 nM (log IC50 =27.760.04) and 67 nM
(log IC50 =27.260.04) for C-furSema3F and C-furSema3A,
respectively. These data confirm that the Sema3 family of ligands
utilize their basic C-terminus for equivalent high-affinity binding
to the Nrp b1b2 domains, and that this binding is competitive with
that of VEGF-A.
Nrp2 and Nrp1Chimera Relieve C-furSema Mediated
Inhibition of AP-VEGF-A Binding to Nrp1
Nrp1 and Nrp2 display similar affinity for Sema3F (Figure 4A
and 4B) but Nrp2 has markedly reduced binding to VEGF-A
relative to Nrp1 (Figure 1). This data suggests that Nrp2 may
be a potent and specific inhibitor of Sema3 binding to Nrp
receptors. To demonstrate the use of Nrp2 as a selective
semaphorin inhibitor, we assayed the ability of Nrp2 to
selectively relieve Sema3-dependent inhibition of VEGF-A
Figure 2. Nrp1 residues mediate specific VEGF-A binding. (A) Alignment of orthologous Nrp1 and Nrp2 b1 domains shows conservation of
residues critical for C-terminal arginine binding (marked with a *) but variability within regions surrounding the interloop cleft (orange: Nrp1:E285/
Nrp2:R287 [9]; green: Nrp1:299-TN-300/Nrp2:301-DGR-303; blue: Nrp1:304-ER-305/Nrp2:307-QQ-308; purple: Nrp1:350-KKK-352/Nrp2:353-QNG-355).
Below the alignment is a conservation histogram illustrating identity across the displayed sequences. (B) Surface representation of the Nrp b1 domain
reveals that the direct VEGF-A binding region (gold) [16] is closely associated with the selected regions (colored according to 2A) in three-dimensional
space. (C) VEGF-A binding of Nrp1 mutants reveals loss of binding for each mutant protein compared to wild-type. Retained AP-Nrp1 binding is
reported as the percent of retained wild-type AP-Nrp1. (D) Determination of the VEGF-A binding capacity of Nrp2 mutants reveals that three of the
four Nrp2 chimeras show enhanced VEGF-A binding compared to wild-type. Retained AP-Nrp2 binding is reported as the percent of retained wild-
type AP-Nrp2. Experiments were performed in triplicate and reported as the mean 61 S.D.
doi:10.1371/journal.pone.0049177.g002
Selective Neuropilin Ligand Binding and Inhibition
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binding. Selectivity would be demonstrated by a reduction of C-
furSema mediated-inhibition and resultant gain in AP-VEGF-A
binding to Nrp1 affinity plates. Nrp1 showed no ability to
relieve the inhibition of Sema3F-mediated inhibition. In fact,
Nrp1 directly sequestered VEGF-A at high Nrp concentrations
resulting in complete loss of binding as expected (black line,
Figure 5). Remarkably, Nrp2 significantly enhanced the amount
of VEGF-A retained on Nrp1 plates to 63% the level of
retention seen in the absence of inhibition (grey line, Figure 5).
This provides direct evidence that Nrp2 is able to directly and
specifically sequester Sema3. Similarly, 37% recovery was seen
with Nrp1Chimera (blue line, Figure 5), consistent with the
reversal of specificity seen for VEGF-A inhibition (Figure 3B).
These data demonstrate that the unique mechanisms utilized by
Nrp to preferentially bind different members of the Sema3 and
VEGF family ligands can be exploited to create Nrp inhibitors
specific for different Nrp ligand families.
Figure 3. NrpChimera molecules exhibit reversed VEGF-A specificity. (A) The secondary structure of WT Nrp and NrpChimera was assessed by
CD. The overlapping spectra of NrpChimera with wild-type Nrp demonstrate that the incorporated mutations are not structurally deleterious. (B)
Nrp1Chimera (blue line) and Nrp2Chimera (green line) were tested for their ability to selectively sequester AP-VEGF-A from Nrp1 adsorbed on affinity
plates. The NrpChimera molecules show reversed VEGF-A specificity with Nrp1Chimera having a marked reduction in inhibitory potency (IC50 = 62 mM)
and Nrp2Chimera exhibiting a significant gain in potency (IC50 = 3.9 mM). Wild-type Nrp1 (black dotted line, IC50 = 1.8 mM) and Nrp2 (grey dotted line,
IC50<310 mM) are shown for comparison (data from Figure 1). Experiments were performed in triplicate and reported as the mean 61 S.D.
doi:10.1371/journal.pone.0049177.g003
Figure 4. Nrp inhibits Sema3F binding through interaction with the C-terminal basic domain. (A) Nrp1 and Nrp2 dependent inhibition of
AP-Sema3F binding to Nrp1 affinity plates was measured. Both Nrp homologues showed similar ability to compete for AP-Sema3F, with Nrp1
inhibiting with an IC50 = 2.0 mM and Nrp2 with an IC50 = 2.7 mM. (B) The ability of Nrp1 and Nrp2 to selectively sequester AP-Sema3F-Ig-basic from
Nrp1 adsorbed on affinity plates was assessed. The amount of retained AP-Sema3F-Ig-basic was measured and the Nrp concentration recorded where
half-inhibition was achieved. Nrp1 (black line) and Nrp2 (grey line) had similar ability for inhibiting Sema3F binding with IC50 = 1.2 mM and
IC50 = 6.2 mM, respectively. (C) Two peptides corresponding to the C-terminal basic domain of Sema3A (C-furSema3A) and Sema3F (C-furSema3F)
were analyzed for their ability to inhibit AP-VEGF-A binding to Nrp1 affinity plates. Both peptides potently inhibited binding with an IC50 = 22 nM and
67 nM for C-furSema3F and C-furSema3A, respectively. Experiments were performed in triplicate and reported as the mean 61 S.D.
doi:10.1371/journal.pone.0049177.g004
Selective Neuropilin Ligand Binding and Inhibition
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Discussion
These data establish the basis for selective Nrp ligand binding to
the b1 coagulation factor domain of Nrp. While both VEGF and
Sema3 ligand families share a partially overlapping ligand binding
site in the Nrp b1 domain [19], we demonstrate a series of residues
that differ between Nrp1 and Nrp2 and contribute to the observed
specific VEGF-A binding.
Nrp2Chimera possesses nearly full reversal of selectivity to the
level of Nrp1, indicating that the three altered regions represent
the predominant regions mediating specific VEGF-A binding. The
TN/DGR L1-loop is highly divergent between Nrp1 and Nrp2
and possesses the only insertion/deletion in the b1 domain.
Mutation of this region results in the largest net loss of VEGF-A
binding to Nrp1, consistent with a direct interaction involving
a hydrogen bond between Nrp1-T299 and VEGF-A-E154 [16].
The KKK/QNG L3-loop produces the largest net gain in Nrp2
binding to VEGF-A. Conserved residues in the L3 loop form one
wall of the C-terminal arginine binding pocket. The non-
conserved KKK/QNG residues do not appear to directly engage
VEGF-A in the bound form. The residues are, however, very
distinct in physical properties with the Nrp1 loop being
significantly more electropositive. VEGF-A contains a series of
conserved acidic residues in the C-terminus of its heparin-binding
domain, including E154 discussed above, which contribute to Nrp
binding. This suggests that the L3-loop may function by
electrostatic steering of VEGF-A. This may represent a general
mechanism allowing specific binding of other Nrp1 specific ligands
such as VEGF-B and placental growth factor (PlGF) that also
possess acidic residues in their heparin-binding domains. In
contrast, Sema3 family members and Nrp2-specific VEGF-C and
VEGF-D do not possess these acidic residues. A mutant Nrp2
containing R287E has previously been shown to possess enhanced
binding to VEGF-A [9]. We show that charge reversal produces
a decrease in Nrp1 binding to VEGF-A indicating a direct
contribution to ligand binding selectivity. Geretti and colleagues
proposed that this may be due to enhancing the electronegative
potential of the b1 domain of Nrp2 favoring binding to the
electropositive VEGF-A. R287 is located in a helical region
directly adjacent to the L1 loop, suggesting that these regions
interact to correctly position these two structural elements, and
thus the critical ligand binding coagulation factor loops. While the
NrpChimera molecules substantially reverse the observed specificity
for VEGF-A, the reversal does not quite reach the corresponding
wild-type level and one or more additional regions may also
contribute to selective binding.
Through understanding the molecular basis for Nrp’s specific
binding of its ligands, engineered soluble Nrp receptors can be
designed with specificity for a particular ligand. The binding of
Sema3F shows little selectivity between Nrp1 and Nrp2. Further,
the observed inhibitory potency of Nrp1 for VEGF-A and Sema3F
is virtually identical in absolute terms. Thus, Nrp1 was found to be
equally capable of sequestering both VEGF-A and Sema3F and
suggests that Nrp1 has utility as a broad-spectrum Nrp ligand
inhibitor. In contrast, Nrp2 is found to selectively sequester
Sema3F. The reported chimeric Nrps have utility for discrimi-
nating between the contribution of VEGF-A and Sema3F function
in a particular system. Previous work has reported Nrp1 mutations
in the a1 domain that allow production of a VEGF-A selective
Nrp1 [25]. The Nrp1Chimera reported here represents a compli-
mentary molecule that is selective for Sema3F, with utility in
differentiating between specific effects mediated by the different
Nrp1 ligands.
The use of soluble Nrp as a modulator of VEGF-mediated
angiogenesis has been the target of numerous studies. Soluble Nrp
as a modality for blocking the chemorepulsive function of Sema3 is
less established even though clear clinical applications exist for
neutralizing molecules in spinal cord injury [30]. The efficacy of
targeting this signaling axis is demonstrated by a small molecule
inhibitor of the Sema3A/Nrp1 interaction [31] that, when given
to rats following spinal cord transection, shows enhanced
regeneration of axons across the glial scar [32]. Two outstanding
issues remain to be solved. First, many members of the Sema3
family can mediate this deleterious axonal repulsion, so a potent
pan-Sema3 inhibitory modality is desired. Second, selective
inhibition of Sema3 signaling without effecting VEGF-A signaling
is desired to maximally promote recovery following injury. Nrp2
molecules engineered for increased potency, by oligomerization
with an Fc or related strategy, have the potential to be used as
selective Sema3-traps. Additionally, molecules specific for certain
members of the Sema3 family could potentially be produced by
combinatorial approaches using the a1 domain of Nrp1/Nrp2 for
specificity in combination with the b1 domain of Nrp2. Taken
together, this study demonstrates the mechanism underlying Nrp
coagulation factor domain-mediated ligand binding selectivity and
advances the search for potent and selective inhibitors of Nrp
signaling.
Supporting Information
Figure S1 Determination of inter-assay variation. The
ability of Nrp1 and Nrp2 to inhibit VEGF-A binding to Nrp1
affinity plates was measured in three independent trials to
determine inter-assay variation. Nrp1 inhibited with an
IC50 = 1.8 mM (orange line), 1.6 mM (red line), and 2.0 mM
Figure 5. Nrp2 and Nrp1Chimera preferentially sequester
Sema3F. The ability of Nrp1, Nrp2, and Nrp1Chimera to selectively
sequester C-furSema was determined through combined incubation of
Nrp, C-furSema3F, and AP-VEGF-A in Nrp1 adsorbed affinity plates. Nrp1
was unable to relieve C-furSema-dependent inhibition and completely
abolished VEGF-A binding (black line). Conversely, titration with Nrp2
promoted 63% recovery of VEGF-A binding demonstrating selective
sequestration of Sema3F (grey line). Nrp1Chimera also relieved C-
furSema-dependent inhibition, promoting recovery of VEGF-A binding
to 37% the level of uninhibited VEGF-A (blue line). Experiments were
performed in triplicate and reported as the mean 61 S.D.
doi:10.1371/journal.pone.0049177.g005
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(yellow line). The average Nrp1 IC50 = 1.8 mM with a standard
deviation of 0.2 mM. At the concentrations tested, Nrp2 was
unable to fully inhibit VEGF-A binding and therefore only an
estimate of the Nrp2 IC50 could be made. Nrp2 inhibited with an
IC50<310 mM (blue line), <120 mM (green line), and <160 mM
(purple line). The average Nrp1 IC50<200 mM with a standard
deviation of 100 mM.
(TIF)
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